Effect of exemestane on the invasive growth of endometrial carcinoma HHUA cells

Objective: To investigate the effect of exemestane on HHUA human endometrial carcinoma cells. Materials and Methods: The HHUA human endometrial carcinoma cells were treated with various concentrations of exemestane, and its effects on cell growth and apoptosis were investigated in vitro. The cell apoptosis was analyzed by flow cytometry and RT-PCR was used to investigate the expression of CD44s. The invasion ability of HHUA human endometrial carcinoma cells which treated with exemestane were assessed using transwell chamber model. Results: At increasing doses of exemestane, a simultaneous increase in apoptotic subpopulations was detected when compared with group A (p < 0.05); the CD44s expression was found to be suppressed after the exemestane treatment. The decrease was a dose-dependent with exemestane treatment. Conclusion: 6×10^-8mol/L exemestane is an optimal dose to inhibit the expression of CD44s mRNA and inhibit the invasive growth of the endometrial carcinoma HHUA cells.

Exemestane; Aromatase; Endometrial neoplasms; Therapy.

[1] Reinhardt M.J.: “Gynecologic tumors. Recent results”. Cancer Res., 2008, 170, 141.

[2] Obel J.C., Friberg G., Fleming G.F.: “Chemotherapy in endome trial cancer”. Clin. Adv. Hematol. Oncol., 2006, 4, 459.

[3] Hill E.K., Dizon D.S.: “Medical therapy of endometrial cancer: current status and promising novel treatments”. Drugs, 2012, 72, 705.

[4] Mendivil A., Schuler K.M., Gehrig P.A.: “Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes”. Cancer Control, 2009, 16, 46.

[5] Musa F., Huang M., Adams B., Pirog E., Holcomb K.: “Mucinous histology is a risk factor for nodal metastases in endometrial cancer”. Gynecol. Oncol., 2012, 125, 541.

[6] Schwartz A.M., Silverberg S.G., Fu Y.S., Nozawa S., Huang S., Tsukasaki K., Williams K.R.: “Use of monoclonal antibodies MSN- 1 and B72.3 in the prediction of the natural history of endometrial hyperplasia”. Int. J. Gynecol. Pathol., 1993, 12, 253.

[7] Zhong B., Cai X., Yi X., Zhou A., Chen S., Su B.: “In vitro and in vivo effects of a cyclooxygenase-2 inhibitor nimesulide analog JCC76 in aromatase inhibitors-insensitive breast cancer cells”. J. Steroid Biochem. Mol. Biol., 2011, 126, 10.

[8] Zhong B., Cai X., Yi X., Zhou A., Chen S., Su B.: “In vitro and in vivo effects of a cyclooxygenase-2 inhibitor nimesulide analog JCC76 in aromatase inhibitors-insensitive breast cancer cells”. J. Steroid Biochem. Mol. Biol., 2011, 126, 10.

[9] Smith I.E., Dowsett M.: “Aromatase inhibitors in breast cancer”. N. Engl. J. Med., 2003, 348, 2431.

[10] Smith I.E., Dowsett M., Yap Y.S.,Walsh G., Lønning P.E., Santen R.J., Hayes D..: “Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines”. J. Clin. Oncol., 2006, 24, 2444.

[11] Gurates B., Sebastian S., Yang S., Zhou J., Tamura M., Fang Z., et al.: “WT1 and DAX-1 inhibit aromatase P450 expression in human endometrial and endometriotic stromal cells”. J. Clin. Endocrinol. Metab., 2002, 87, 4369.

[12] Buzdar A., Howell A.: “Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer”. Clin. Cancer Res., 2001, 7, 2620.

[13] Li F., Devi Y.S., Bao L., Mao J., Gibori G.: “Involvement of cyclin D3, CDKN1A (p21), and BIRC5 (CD44s) in interleukin 11 stimulation of decidualization in mice”. Biol. Reprod., 2008, 78, 127.

[14] Auzenne E., Ghosh S.C., Khodadadian M., Rivera B., Farquhar D., Price R.E., et al.: “Hyaluronic acid-paclitaxel: antitumor efficacy against CD44 (+) human ovarian carcinoma xenograft-s”. Neoplasia, 2007, 9, 479.

[15] Afify A., Pang L., Howell L.: “Diagnostic utility of CD44 standard, CD44v6, and CD44v3-10 expression in adenocarcinomas presenting in serous fluids”. Appl. Immunohistochem. Mol. Morphol., 2007, 15, 446. [16] Ponta H., Sheman L., Herrlich P.A.: “CD44: from adhesion molecules to signaling regulators”. Nat. Rev. Mol. Cell. Biol., 2003, 4, 33.